Naomi J. Patel

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet et al. · Annals of the Rheumatic Diseases · 2021 · 236 citations · Full text

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Zara Izadi, Erica J. Brenner, Satveer K. Mahil et al. · JAMA Network Open · 2021 · 114 citations · Full text

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Manuel F. Ugarte‐Gil, Graciela S. Alarcón, Zara Izadi et al. · Annals of the Rheumatic Diseases · 2022 · 88 citations · Full text

DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study

Michael Di Iorio, Claire Cook, Kathleen M.M. Vanni et al. · Seminars in Arthritis and Rheumatism · 2022 · 63 citations · Full text

Rheumatology, Long Covid, Autoimmune Disease +11

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

Sharon Nachman, Naiyu Zheng, Edward P. Acosta et al. · Clinical Infectious Diseases · 2013 · 59 citations · Full text